

Annex to news: ECHA's Biocides Committee backs approval of anticoagulant rodenticides

Helsinki, 21 May 2025

Information about the opinions

See [product-types](#)

Active substances

Opinions on the following active substances were adopted:

3-iodo-2-propynylbutylcarbamate (IPBC) for product-type 10

IPBC has been evaluated for use as a fungicide for preservation of building materials, other than wood (PT10). IPBC is intended to be incorporated into plasters, sealants and fillers to control fungal attack in or on building materials (treated articles) in-use. Preservation of building materials provides continuous protection as the preservative is applied to the treated article before use.

The BPC adopted its opinion on the approval of IPBC for product-type 10 by simple majority of the members having the right to vote.

Denmark is the evaluating competent authority of this application.

Brodifacoum for product-type 14

Brodifacoum is a vitamin K antagonist. It disrupts the normal blood clotting mechanisms resulting in increased bleeding tendency and, eventually, haemorrhage and death. It is used for the control of mice and rats.

The BPC adopted its opinion on the renewal of Brodifacoum for product-type 14 by simple majority of the members having the right to vote.

The Netherlands is the evaluating competent authority of this application.

Flocoumafen for product-type 14

Flocoumafen is a vitamin K antagonist. It disrupts the normal blood clotting mechanisms resulting in increased bleeding tendency and, eventually, haemorrhage and death. It is used for the control of mice and rats.

The BPC adopted its opinion on the renewal of Flocoumafen for product-type 14 by simple majority of the members having the right to vote.

The Netherlands is the evaluating competent authority of this application.

Coumatetralyl for product-type 14

Coumatetralyl is a vitamin K antagonist. It disrupts the normal blood clotting mechanisms resulting in increased bleeding tendency and, eventually, haemorrhage and death. It is used for the control of mice and rats.

The BPC adopted its opinion on the renewal of Coumatetralyl for product-type 14 by simple majority of the members having the right to vote.

Denmark is the evaluating competent authority of this application.

Chlorophacinone for product-type 14

Chlorophacinone is a vitamin K antagonist. It disrupts the normal blood clotting mechanisms resulting in increased bleeding tendency and, eventually, haemorrhage and death. It is used for the control of mice and rats.

The BPC adopted its opinion on the renewal of Chlorophacinone for product-type 14 by simple majority of the members having the right to vote.

Spain is the evaluating competent authority of this application.

Difethialone for product-type 14

Difethialone is a vitamin K antagonist. It disrupts the normal blood clotting mechanisms resulting in increased bleeding tendency and, eventually, haemorrhage and death. It is used for the control of mice and rats.

The BPC adopted its opinion on the renewal of Difethialone for product-type 14 by simple majority of the members having the right to vote.

Norway is the evaluating competent authority of this application.

Difenacoum for product-type 14

Difenacoum is a vitamin K antagonist. It disrupts the normal blood clotting mechanisms resulting in increased bleeding tendency and, eventually, haemorrhage and death. It is used for the control of mice and rats.

The BPC adopted its opinion on the renewal of Difenacoum for product-type 14 by simple majority of the members having the right to vote.

Finland is the evaluating competent authority of this application.

Bromadiolone for product-type 14

Bromadiolone is a vitamin K antagonist. It disrupts the normal blood clotting mechanisms resulting in increased bleeding tendency and, eventually, haemorrhage and death. It is used for the control of mice and rats.

The BPC adopted its opinion on the renewal of Bromadiolone for product-type 14 by simple majority of the members having the right to vote.

France is the evaluating competent authority of this application.

Alpha-bromadiolone for product-type 14

Alpha-bromadiolone is a vitamin K antagonist. It disrupts the normal blood clotting mechanisms resulting in increased bleeding tendency and, eventually, haemorrhage and death. It is used for the control of mice and rats.

The BPC adopted its opinion on the approval of Alpha-bromadiolone for product-type 14 by simple majority of the members having the right to vote.

France is the evaluating competent authority of this application.

Harmonised List of Endpoints for pyrethroid metabolites – Environmental hazards

The BPC discussed and agreed on the revision of the Pyrethroid metabolites harmonised List of Endpoints (LoEP) document for environmental hazards. The first version of the LoEP was adopted by the BPC in September 2020 (BPC-35). The revision focused on the update of DT50 values according to latest guidance. The document will be published on ECHA's website.

ECHA acted as a rapporteur for this case.

Union authorisations

Opinions on the following products / product families were adopted:

Biocidal product family containing Active chlorine released from hypochlorous acid for product-type 1 and 3

The products of the biocidal product family contain the active substance active chlorine released from hypochlorous acid and are intended for use as disinfectant for human hygiene in non-medical applications by professional and non-professional users (product-type 1).

The BPC adopted its opinion on the authorisation of the biocidal product family by consensus.

Denmark is the evaluating competent authority of this application.

Biocidal product Potassium (E,E)-hexa-2,4-dienoate (Potassium Sorbate) for product-type 6

The biocidal product is for industrial use only and used as a preservative for products during storage (product-type 6).

The BPC adopted its opinion on the authorisation of the biocidal product by consensus.

Denmark is the evaluating competent authority of this application.

Biocidal product family containing Hydrogen peroxide for product-types 2, 3 and 4

The products in the biocidal product family are disinfectants with various uses in the following product-types: disinfectants and algaecides not intended for direct application to humans or animals (product-type 2), veterinary hygiene (product-type 3) and food and feed area (product-type 4).

The BPC adopted its opinion on the authorisation of the biocidal product family by consensus.

The Netherlands is the evaluating competent authority of this application.

Biocidal product family containing Hydrogen peroxide for product-types 3 and 4

The members of the Hydrogen Peroxide Products family are disinfectants (PT3, PT4) used by professional users. The ready-to-use (RTU) products can be used for pre-milking teat disinfection via spraying, foaming, dipping with cup or automated in-liner dipping. The product family is also used for disinfection and cleaning of inner surfaces in milking machine pipelines and milk storage tanks.

The BPC adopted its opinion on the authorisation of the biocidal product family by consensus.

The Netherlands is the evaluating competent authority of this application.

Major change of a Union authorisation of a biocidal product containing pyriproxyfen and (E)-1-(2-Chloro-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine (Clothianidin) for product-type 18

The proposed change concerned the change of composition of the non-active ingredients.

The BPC adopted its opinion on the authorisation of the major change by consensus.

The Netherlands is the evaluating competent authority of this application.

Article 75(1)(g) request from the European Commission

Draft BPC opinion on "Updates of the risk assessment and risk mitigation measures for use against fungi by professionals and of the PAR, SPC and BPC Opinion of the Union Authorisation 'Hydrogen Peroxide Product Family'"

A revised opinion, a product authorisation report (PAR) and draft summary of product characteristics (SPC) were prepared, addressing the risk assessment of the use of products containing 5% H₂O₂ against fungi by spraying, wiping and mopping and the specific risk mitigation measures if required, and the alignment of the descriptions of the application methods in the SPC.

The BPC adopted the opinion by consensus.

The Netherlands is the evaluating competent authority for this opinion.

Article 38 requests from the European Commission

Draft BPC opinion on "Question on unresolved objections during a mutual recognition procedure in accordance with Article 36(1) of Regulation (EU) No 528/2012 of a PT 3 biocidal product intended for hard surface disinfection"

The BPC adopted the opinion by consensus.

The rapporteur for this opinion is ECHA.

Draft BPC opinion on "Question on unresolved objections during a mutual recognition procedure in accordance with Article 36(1) of Regulation (EU) No 528/2012 of a PT 2 biocidal product intended for hard surface disinfection"

The BPC adopted the opinion by consensus.

The rapporteur for this opinion is ECHA.

Draft BPC opinion on "Question on unresolved objections during a mutual recognition procedure in accordance with Article 36(1) of Regulation (EU) No 528/2012 of a PT 19 biocidal product intended to be used by non-professional users on human skin to repel house mosquitoes"

The BPC adopted the opinion by simple majority.

The rapporteur for this opinion is ECHA.